arrow
F

Francesco Bertoni

Institute of Oncology Research
H指数:95
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

SAKK 35/14随机试验:利妥昔单抗联合或不联合伊布替尼治疗初治滤泡性淋巴瘤患者

2026-09-060
OAAI
Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis

调节因子X 7在b细胞活化过程中限制Myc活性并抑制Myc依赖性淋巴瘤发生

2026-06-010
PRE
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma—SAKK 66/18 Trial

Ib期临床试验:Copanlisib联合Venetoclax治疗复发或难治性B细胞非霍奇金淋巴瘤——SAKK 66/18试验

Cancers
IF4.4
2026-05-280
OAAI
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies

Sasi, B.K.; Tarantelli, C.; Martindale, S.; Civanelli, E.; Cannas, E.; Sartori, G.; Arribas, A.J.; Fernandes, S.M.; Shupe, S.J.; Machado, J.H.; 等. 新型PI3kδ抑制剂roginolisib与venetoclax在血液系统恶性肿瘤中具有协同作用。Haematologica 2025. [Google Scholar] [CrossRef] [PubMed]

2025-12-012
OAAI
A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL

一种高通量骨髓3D共培养系统,用于研究B-NHL对BCR信号靶向药物的抗性

2025-12-010
OAAI
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial

基因突变与拷贝数变异的整合优化了套细胞淋巴瘤的预后:意大利淋巴瘤基金会MCL0208临床试验的长期结果

Leukemia
IF13.4
2025-11-070
OAAI
Comprehensive analysis of 177Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes

177Lu-lilotomab satetraxetan在淋巴瘤细胞系中的综合分析:对精准放射免疫治疗和联合方案的意义

2025-09-180
PRE
Chemosensor receptors are lipid-detecting regulators of macrophage function in cancer

化学传感器受体是癌症中巨噬细胞功能的脂质检测调节剂

2025-06-300
OAAI
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype

PIM激酶的靶向在ABC亚型的弥漫性大b细胞淋巴瘤中显示出单一药物的功效,并与BCL2抑制剂协同作用

2025-03-010
PRE